Skip to main content
Delfa

← All trials/NCT06243536

UnknownPhase 4

The Effect of Semaglutide on Disordered Eating Behaviour in Type 2 Diabetic Patients

Asset

Semaglutide

GLP-1 agonist

Listed sites

1

Recruiting sites

-

Estimated enrollment

60

Study population

Feeding And Eating Disorders, Obesity / overweight, Type 2 diabetes

Eligibility highlights

•BMI ≥28•HbA1c ≥7%

Primary endpoint

•Eating Attitude Test (EAT-26) questionnaire score

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT06243536
Org study ID251-29-1 1/3-23-06

Timeline

Milestones

Study start2024-02-01estimated
Study first posted2024-02-06actual
Last update posted2024-02-06actual
Primary completion2024-12-31estimated
Study completion2024-12-31estimated

Assets

Investigational agents

Semaglutide

Who this study enrolls

Feeding And Eating DisordersObesity / overweightType 2 diabetes

Who can enroll

Minimum age18 Years
Maximum age65 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

•type 2 diabetes, age 18-65, BMI ≥28 kg/m2, HbA1c>7%, glp-1 receptor agonist naïve

Exclusion criteria

•hepatic impairment (Child Pugh score C), renal impairment (eGFR<30 ml/min), use of medication that affect eating (GLP-1 receptor agonists, antidepressants, antiobesity medications, glucocorticoids, insulin, oral contraceptives, hormonal therapy), conditions that can affect eating (hypothyroidism, hyperthyroidism, Cushing syndrome, acromegaly, adrenal insufficiency, pregnancy, breastfeeding), contraindications for semaglutide

Endpoints (3)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Glycemic / diabetes
1
Patient-reported / QoL
1
Other (unclassified)
1

Glycemic / diabetes

1 endpoint
Secondary/protocol endpoint/low confidence

Continuous glucose monitoring parameter (Glycemic Variability)

Time frame:CGM parameter will be assessed through 14 days at the beginning of the trial and through 14 days at the end of the trial after 12 weeks.

descriptive, improvement

Patient-reported / QoL

1 endpoint
Primary/protocol endpoint

Eating Attitude Test (EAT-26) questionnaire score

Time frame:EAT-26 questionnaire will be assessed at the beginning of the trial and at the end of the trial after 12 weeks.

change from baseline, improvement

Other (unclassified)

1 endpoint
Secondary/protocol endpoint/low confidence

Concentration of incretin hormones (GLP-1, GIP)

Time frame:At the beginning of the trial (before semaglutide administration)

concentration, descriptive

Publications (37)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 6, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 6, 2026 snapshot.